PTC Therapeutics to buy ST-920 Fabry gene therapy for $111M
PTC Therapeutics agreed to buy Sangamo’s ST-920 Fabry gene therapy for $111M, with $100M in milestones.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.